Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $15.74 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $14.31, a 51.91% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $9.42, a 9.41% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.61.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $12.60, a 4.18% decline from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $13.15, a 692.17% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.66.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.74 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $14.31 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $12.60 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $11.07 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $11.13 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $9.42 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $13.15 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $12.60 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $9.14 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $8.61 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $1.66 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $1.66 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $7.97 10-K · filed 2022-03-08 | |||
| 2020-12-31 | $6.87 10-K · filed 2021-03-03 | |||
| 2019-12-31 | $6.87 10-K · filed 2020-03-03 | |||
| 2018-12-31 | $7.71 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |